Wells Fargo & Company Aveo Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$8.48 - $14.97 $890 - $1,571	105 Added 57.07%	289 $4,000
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $1,844 - $2,432	-279 Reduced 60.26%	184 $2,000
Q2 2022 Aug 12, 2022	SELL	$3.51 - $6.67 $5,205 - $9,891	-1,483 Reduced 76.21%	463 $3,000
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $1,275 - $2,434	-405 Reduced 17.23%	1,946 $10,000
Q4 2021 Feb 14, 2022	BUY	$4.69 - $7.4 $4 - $7	1 Added 0.04%	2,351 $11,000
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $5 - $6	-1 Reduced 0.04%	2,350 $14,000
Q2 2021 Aug 16, 2021	SELL	$6.21 - $7.45 $40,470 - $48,551	-6,517 Reduced 73.49%	2,351 $15,000
Q1 2021 May 13, 2021	SELL	$5.97 - $15.28 $186,455 - $477,224	-31,232 Reduced 77.89%	8,868 $65,000
Q4 2020 Feb 09, 2021	SELL	$5.08 - $6.68 $64,602 - $84,949	-12,717 Reduced 24.08%	40,100 $231,000
Q3 2020 Nov 05, 2020	BUY	$4.16 - $6.26 $89,872 - $135,241	21,604 Added 69.21%	52,817 $313,000
Q2 2020 Aug 13, 2020	BUY	$3.47 - $9.99 $19,282 - $55,514	5,557 Added 21.66%	31,213 $161,000
Q1 2020 May 14, 2020	BUY	$2.6 - $6.9 $66,705 - $177,026	25,656 New	25,656 $93,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.